H. Lundbeck A/S (HLUBF)

Market Cap	5.58B +3.1%
Revenue (ttm)	3.87B +11.9%
Net Income	501.82M +1.6%
EPS	0.51 +1.5%
Shares Out	n/a
PE Ratio	11.12
Forward PE	6.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1,189
Open	4.820
Previous Close	4.820
Day's Range	4.820 - 4.820
52-Week Range	3.665 - 6.410
Beta	0.30
RSI	43.91
Earnings Date	May 13, 2026

About H. Lundbeck

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1915
• Employees: 5,039
• Stock Exchange: OTCMKTS
• Ticker Symbol: HLUBF

Financial Performance

In 2025, H. Lundbeck's revenue was 24.63 billion, an increase of 11.93% compared to the previous year's 22.00 billion. Earnings were 3.19 billion, an increase of 1.56%.

Financial numbers in DKK